| Phase 11 trial |
|
Phase 1
|
NCT04606472 |
Nov 2020 → Dec 2025 overdue |
cancer |
Sichuan Baili Pharmaceutical Co., Ltd. |
Active not recruiting
|
No outcome recorded
|
| Phase 1/22 trials |
|
Phase 1/2
|
NCT05949606 |
Oct 2023 → Dec 2026 expected |
non-small cell lung carcinoma |
Sichuan Baili Pharmaceutical Co., Ltd. |
Recruiting
|
No outcome recorded
|
|
Phase 1/2
|
NCT05668858 |
Feb 2023 → Dec 2026 expected |
head and neck squamous cell carcinoma |
Sichuan Baili Pharmaceutical Co., Ltd. |
Recruiting
|
No outcome recorded
|
| Phase 28 trials |
|
Phase 2
|
NCT06668961 |
Nov 2024 → Nov 2026 expected |
head and neck squamous cell carcinoma |
Sichuan Baili Pharmaceutical Co., Ltd. |
Recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT05956587 |
Jan 2024 → Dec 2026 expected |
nasopharyngeal carcinoma, non-small cell lung carcinoma |
Sichuan Baili Pharmaceutical Co., Ltd. |
Recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT06042894 |
Dec 2023 → Dec 2026 expected |
breast cancer |
Sichuan Baili Pharmaceutical Co., Ltd. |
Recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT05965856 |
Dec 2023 → Dec 2026 expected |
urothelial carcinoma |
Sichuan Baili Pharmaceutical Co., Ltd. |
Recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT06008054 |
Nov 2023 → Dec 2026 expected |
colorectal cancer, esophageal cancer, gastric cancer |
Sichuan Baili Pharmaceutical Co., Ltd. |
Recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT05924841 |
Nov 2023 → Dec 2026 expected |
small cell lung carcinoma |
Sichuan Baili Pharmaceutical Co., Ltd. |
Recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT05990803 |
Nov 2023 → Dec 2026 expected |
cervical cancer |
Sichuan Baili Pharmaceutical Co., Ltd. |
Recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT06006169 |
Oct 2023 → Dec 2026 expected |
head and neck squamous cell carcinoma |
Sichuan Baili Pharmaceutical Co., Ltd. |
Recruiting
|
No outcome recorded
|